Replies to post #118983 on Biotech Values

[DewDiligence]

SNY’s 1Q11 US Lovenox sales were down 5% to €222M (from €233M in 4Q10): http://en.sanofi-aventis.com/binaries/20110428_Q12011_en_tcm28-31968.pdf (page 15).

At the average exchange rate during 1Q11, the €222M translates into roughly $310M. Since NVS sold $247M of generic Lovenox in 1Q11, we now know that NVS had a 44% share of in-market dollar sales during the quarter, which is consistent with what NVS said on its 1Q11 CC.